celltrion healthcare
Scope
Date
~
-
Bio & Pharma
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
Apr 28, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Apr 17, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Apr 10, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
Mar 25, 2025 (Gmt+09:00)
-
Shareholder value
Celltrion to cancel $140 mn in treasury shares, stock up
South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of treasury shares to i...
Mar 14, 2025 (Gmt+09:00)
-
Bio & Pharma
Samsung, Celltrion lead biosimilar market in Europe, US
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...
Mar 10, 2025 (Gmt+09:00)
-
Mergers & Acquisitions
CHA Biotech seeks to resume healthcare unit IPO after affiliates’ merger
CHA Biotech Co., South Korea’s leading stem cell therapeutics developer, plans to resume an initial public offering of CHA Healthcare Co., a m...
Feb 26, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Feb 25, 2025 (Gmt+09:00)
-
Private equity
EQT targets healthcare, technology, business service providers in Korea
EQT, the largest private equity firm in Europe, is setting its sights on healthcare, technology companies and business service providers in South Ko...
Feb 14, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe
South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...
Feb 05, 2025 (Gmt+09:00)
-
Bio & Pharma
Partners Investment, GordonMD eye $150 mn biotech fund launch
South Korean venture capital firm Partners Investment said on Thursday it will raise up to 215.5 billion won ($150 million) in a biotech fund jointl...
Jan 23, 2025 (Gmt+09:00)
-
IPOs
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
Jan 16, 2025 (Gmt+09:00)
-
Bio & Pharma
Korean drugmakers control more than half of European biosimilar market
South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...
Jan 02, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion obtains approval of Steqeyma from FDA
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...
Dec 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion BioSolutions launched to venture into CDMO
Celltrion Inc. on Tuesday launched its contract development and manufacturing organization unit Celltrion BioSolutions Co. in its foray into the CDM...
Dec 17, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s 4 new biosimilars win EU approval recommendation
Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...
Dec 16, 2024 (Gmt+09:00)
-
Markets
Celltrion to allot cash, stock dividend at once
South Korea’s biosimilar maker Celltrion Inc. on Friday announced a plan to allot cash and stock dividends simultaneously. The company wi...
Dec 13, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets approval of Omlyclo in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...
Dec 09, 2024 (Gmt+09:00)
-
Aerospace & Defense
Boryung invests $10 million in Intuitive Machines
South Korea's Boryung Corp. said on Friday it bought $10.0 million in shares of US-based lunar lander company Intuitive Machines to expand its space...
Dec 06, 2024 (Gmt+09:00)
-
Shareholder value
Celltrion to retire $400 mn treasury stock in January
South Korea’s biosimilar maker Celltrion Inc. on Wednesday announced a plan to retire about a quarter of its treasury stock worth 563 billion ...
Dec 04, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to break ground on CDMO plant in 2025: Chairman Seo
South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...
Nov 28, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug
Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...
Nov 25, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to acquire additional $72 mn in treasury shares
South Korea's Celltrion Inc. announced on Thursday that it decided to repurchase additional treasury shares worth 100 billion won ($71.6 million).Fr...
Nov 21, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion acquires Swiss pharmaceutical distributor iQone
South Korea's Celltrion Inc. said on Friday that it completed its acquisition of iQone Healthcare Switzerland, a Swiss pharmaceutical distributor, t...
Nov 15, 2024 (Gmt+09:00)
-
Korean stock market
MSCI Korea Index adds Hyundai Rotem
MSCI announced on Wednesday that South Korea's Hyundai Rotem Co. will be added to the Morgan Stanley Capital International (MSCI) Korea Index. ...
Nov 07, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Steqeyma in Europe
South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...
Nov 05, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Zymfentra gets 90% distribution channel in US
South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...
Oct 30, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to establish CDMO subsidiary
Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organiza...
Oct 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion's anti cancer drugs hold 90% market share in C.America
South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....
Oct 11, 2024 (Gmt+09:00)
-
Electronics
LG NOVA hosts Innovation Festival in US
LG Electronics Inc. 's North American Innovation Center (LG NOVA) said on Monday that it held an Innovation Festival last Wednesday and Thursday at ...
Sep 30, 2024 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand